AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Daily Turnover | The turnover of Exelixis on 8/4 was $161.25 Million, Ranking 618
ByAinvest
Monday, Aug 4, 2025 6:00 pm ET1min read
The turnover of Exelixis on 8/4/2025 was $161.25 million, ranking 618 in today's market, the Volume is 4.38 million.
Exelixis(EXEL) shares closed at $36.81, down 1.21% on 8/4/2025, down 17.08% in the last 5 trading days, up 1.63% this month, up 10.54% year-to-date and up 56.51% in the last 52 weeks.
*If the company has been listed for less than 52 weeks, the 52-week gain is the gain since the listing.
(The same applies for less than 1 month, or less than 5 trading days)
【History Turnover】
| Date | Turnover | Volume | Price | Performance |
|---|---|---|---|---|
| 8/4/2025 | $161.25 million | 4.38 million | $36.81 | -1.21% |
| 8/1/2025 | $216.35 million | 5.81 million | $37.26 | 2.87% |
| 7/31/2025 | $178.93 million | 4.88 million | $36.22 | -1.72% |
| 7/30/2025 | $191.61 million | 5.15 million | $36.855 | -0.23% |
| 7/29/2025 | $588.08 million | 15.74 million | $36.94 | -16.78% |
【Company Profile】
Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer.The comapny was incorporated in Delaware in November 1994 as Exelixis Pharmaceuticals, Inc., and the comapny changed its name to Exelixis, Inc. in February 2000. The comapny is focusing its proprietary resources and development and commercialization efforts exclusively on COMETRIQ (cabozantinib), itd wholly-owned inhibitor of multiple receptor tyrosine kinases. The comapny's objective is to develop COMETRIQ into a major oncology franchise, and the comapny believes that the approval of COMETRIQ for the treatment of progressive, metastatic MTC provides it with the opportunity to establish a commercial presence in furtherance of this objective.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet